BioSpace News Archive

Tilray, Inc. (NASDAQ: TLRY), a global leader in cannabis research and production, today announced that it partnered with researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney to complete a study examining the effects of cannabis on driving and cognitive function.

HemaCare Corporation today announced the company has moved its global headquarters to Northridge, California.

Puma Biotechnology, Inc. announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from the Company’s Phase III ExteNET Trial of neratinib for early stage HER2-Amplified breast cancer are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.

The FDA is committed to doing what is can to stimulate the development of more products by improving the consistency and efficiency fueling biotech and pharma companies in the pharmaceutical industry forge ahead seeking positive results of clinical trials towards new treatments for various rare diseases, including numerous forms of cancer.

Chemistree is now underway with establishing the Sugarleaf brand in California

US Patent 10,136,929 entitled “Flexible Bone Implant” is the first patent to issue from the intellectual property portfolio held by the company that includes additional pending US and international patent applications.

This year, joimax® is focusing on their Endoscopic Tower Generation 4 Devices, an expert solution for spinal surgery.

ValueHealth™ is pleased to announce Muve Lakeway Ambulatory Surgery Center (ASC) and Muve Lakeway Surgical Stay Suites, the flagship knee and hip replacement surgery center of Muve Health, LLC, have received The Joint Commission’s Gold Seal of Approval® for Advanced Certification for Total Hip and Total Knee Replacement.

Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system used with implanted left ventricular assist devices (LVADs), announces the successful completion of a 180-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump.

This is in line with the World Health Organizations’ Global Action Plan on Physical Activity, which aims to address the dramatic growth in lifestyle diseases, caused in part by a lack of exercise.